Affymax implosion highlights risk in biotechnology stocks
News | 25 February 2013
It has been a tough start to the week for shareholders in Affymax (AFFY), with the company's stock selling off 85% at the open Monday morning. The the selloff highlights the inherent risks associated with investing in biotech companies, where fortunes ...
Click on the link to read the full article at Market Intelligence Center
(This link will open in a new window)
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
